Literature DB >> 6349862

Development and optimisation of a radioimmunoassay for plasma captopril.

F M Duncan, V I Martin, B C Williams, E A Al-Dujaili, C R Edwards.   

Abstract

A specific and sensitive radioimmunoassay has been developed to monitor plasma levels of captopril, the first orally active angiotensin-converting enzyme inhibitor. Because of the reactive nature of the captopril thiol group, captopril was measured as the captopril-N-ethylmaleimide complex (captopril-NEM). Accuracy studies, using samples with known added concentrations of captopril, were satisfactory (r = 0.95, p less than 0.001, y = 0.97x - 2.02), and the radioimmunoassay results compared well with those determined by a gas chromatography/mass spectrometric method (r = 0.98, p less than 0.0005, y = 1.2x - 19). The minimum detection limit of the assay was 2 micrograms captopril/litre plasma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349862     DOI: 10.1016/0009-8981(83)90099-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure.

Authors:  T R Shaw; F M Duncan; B C Williams; E Crichton; S A Thomson; J R Davis; M Rademaker; C R Edwards
Journal:  Br Heart J       Date:  1985-08

Review 2.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  2D-Single-crystal hexagonal gold nanosheets for ultra-trace voltammetric determination of captopril.

Authors:  Mehdi Shahbakhsh; Meissam Noroozifar
Journal:  Mikrochim Acta       Date:  2019-02-19       Impact factor: 5.833

4.  Intravenous captopril treatment in patients with severe cardiac failure.

Authors:  M Rademaker; T R Shaw; B C Williams; F M Duncan; J Corrie; A Eglen; C R Edwards
Journal:  Br Heart J       Date:  1986-02

Review 5.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.